Denong Wang1, Xiaohe Liu2, Ben Hsieh3, Richard Bruce3, George Somlo4, Jiaoti Huang5, Lidia Sambucetti2. 1. Tumor Glycomics Laboratory, Menlo Park, California, USA; SRI International Biosciences Division, Menlo Park, California, USA. Electronic address: denong.wang@sri.com. 2. SRI International Biosciences Division, Menlo Park, California, USA. 3. Palo Alto Research Center, Palo Alto, California, USA. 4. Departments of Medical Oncology and Therapeutics Research, City of Hope Cancer Center, Duarte, California, USA. 5. Department of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Abstract
BACKGROUND AND AIMS: Recognition of abnormal glycosylation in virtually every cancer type has raised great interest in exploration of the tumor glycome for biomarker discovery. Identifying glycan markers of circulating tumor cells (CTCs) represents a new development in tumor biomarker discovery. The aim of this study was to establish an experimental approach to enable rapid screening of CTCs for glycan marker identification and characterization. METHODS: We applied carbohydrate microarrays and a high-speed fiber-optic array scanning technology (FAST scan) to explore potential glycan markers of breast CTCs (bCTCs) and targeting antibodies. An anti-tumor monoclonal antibody, HAE3-C1 (C1), was identified as a key immunological probe in this study. RESULTS: In our carbohydrate microarray analysis, C1 was found to be highly specific for an O-glycan cryptic epitope, gp(C1). Using FAST-scan technology, we established a procedure to quantify expression levels of gp(C1) in tumor cells. In blood samples from five stage IV metastatic breast cancer patients, the gp(C1) positive CTCs were detected in all subjects; ∼40% of bCTCs were strongly gp(C1) positive. Interestingly, CTCs from a triple-negative breast cancer patient with multiple sites of metastasis were predominantly gp(C1) positive (92.5%, 37/40 CTCs). CONCLUSIONS: Together we present here a practical approach to examine rare cell expression of glycan markers. Using this approach, we identified an O-core glyco-determinant gp(C1) as a potential immunological target of bCTCs. Given its bCTC-expression profile, this target warrants an extended investigation in a larger cohort of breast cancer patients.
BACKGROUND AND AIMS: Recognition of abnormal glycosylation in virtually every cancer type has raised great interest in exploration of the tumor glycome for biomarker discovery. Identifying glycan markers of circulating tumor cells (CTCs) represents a new development in tumor biomarker discovery. The aim of this study was to establish an experimental approach to enable rapid screening of CTCs for glycan marker identification and characterization. METHODS: We applied carbohydrate microarrays and a high-speed fiber-optic array scanning technology (FAST scan) to explore potential glycan markers of breast CTCs (bCTCs) and targeting antibodies. An anti-tumor monoclonal antibody, HAE3-C1 (C1), was identified as a key immunological probe in this study. RESULTS: In our carbohydrate microarray analysis, C1 was found to be highly specific for an O-glycan cryptic epitope, gp(C1). Using FAST-scan technology, we established a procedure to quantify expression levels of gp(C1) in tumor cells. In blood samples from five stage IV metastatic breast cancerpatients, the gp(C1) positive CTCs were detected in all subjects; ∼40% of bCTCs were strongly gp(C1) positive. Interestingly, CTCs from a triple-negative breast cancerpatient with multiple sites of metastasis were predominantly gp(C1) positive (92.5%, 37/40 CTCs). CONCLUSIONS: Together we present here a practical approach to examine rare cell expression of glycan markers. Using this approach, we identified an O-core glyco-determinant gp(C1) as a potential immunological target of bCTCs. Given its bCTC-expression profile, this target warrants an extended investigation in a larger cohort of breast cancerpatients.
Authors: D Haidopoulos; M M Konstadoulakis; P T Antonakis; D G Alexiou; A M Manouras; S M Katsaragakis; G F Androulakis Journal: Eur J Surg Oncol Date: 2000-12 Impact factor: 4.424
Authors: Denong Wang; Laila Dafik; Rosalie Nolley; Wei Huang; Russell D Wolfinger; Lai-Xi Wang; Donna M Peehl Journal: Drug Dev Res Date: 2013-03 Impact factor: 4.360
Authors: Jorge L Yao; Patricia A Bourne; Qi Yang; Junyi Lei; P Anthony di Sant'Agnese; Jiaoti Huang Journal: Arch Pathol Lab Med Date: 2004-07 Impact factor: 5.534